Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Maternal and pediatric nutrition

Risk factors associated with extraintestinal manifestations in children with inflammatory bowel disease

Abstract

Objectives

Extraintestinal manifestations (EIM) are common complications of inflammatory bowel disease (IBD) associated with morbidity and reduced quality of life (QOL). The aim of this study was to identify and validate predictors for EIM in children with IBD.

Methods

The medical records of children with IBD were retrospectively reviewed, and EIM present before diagnosis and those detected during follow-up, were recorded.

Results

One-hundred children were included, and their median age (interquartile range) was 13.9 (11.9–15.2) years. Forty-six (46%) children had EIM, including 10 (10%) whose EIM was present before diagnosis and 36 (36%) during follow-up. The most common EIMs were aphthous stomatitis (18%), arthralgia (14%), dermatologic manifestations (8%), and arthritis (6%). A body mass index in the lower or upper quartile (hazard ratio [HR] 9.30 and 23.71, respectively, p < 0.001), moderate-to-severe disease activity (HR 4.43, p < 0.001), extensive Crohn’s disease (HR 3.43, p= 0.025), lower hemoglobin level (HR 2.29, p < 0.001), lower albumin level (HR 2.86, p = 0.029), and higher C-reactive protein level (HR 1.04, p < 0.001) at diagnosis were identified as risk factors for EIM during follow-up.

Conclusions

Identification of risk factors at IBD diagnosis may help healthcare providers to predict EIM in children with IBD and to improve their management for lessening morbidity and enhancing QOL.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Vavricka SR, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD Cohort Study. Inflamm Bowel Dis. 2017;23:1174–81.

    Article  Google Scholar 

  2. 2.

    Isene R1, Bernklev T, Høie O, Munkholm P, Tsianos E, Stockbrügger R, et al. Extraintestinal manifestations in Crohn’s disease and ulcerative colitis: Results from a prospective, population-based European inception cohort. Scand J Gastroenterol. 2015;50:300–5.

    Article  Google Scholar 

  3. 3.

    Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease: Prevalence, presentation, and anti-TNF treatment. J Pedia Gastroenterol Nutr. 2017;65:200–6.

    CAS  Article  Google Scholar 

  4. 4.

    Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110–9.

    Article  Google Scholar 

  5. 5.

    Trost LB, McDonnell JK. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J. 2005;81:580–5.

    CAS  Article  Google Scholar 

  6. 6.

    Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1424–9.

    Article  Google Scholar 

  7. 7.

    Mir-Madjlessi SH, Taylor JS, Farmer RG. Clinical course and evolution of erythema nodosum and pyoderma gangrenosum in chronic ulcerative colitis: a study of 42 patients. Am J Gastroenterol. 1985;80:615–20.

    CAS  PubMed  Google Scholar 

  8. 8.

    Ott C, Schölmerich J. Extraintestinal manifestations and complications in IBD. Nat Rev Gastroenterol Hepatol. 2013;10:585–95.

    CAS  Article  Google Scholar 

  9. 9.

    Vavricka SR, Gantenbein C, Spoerri M, Spoerri M, Prinz Vavricka M, Navarini AA, et al. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21:1794–1800.

    Article  Google Scholar 

  10. 10.

    Karmiris K, Avgerinos A, Tavernaraki A, Zeglinas C, Karatzas P, Koukouratos T, et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J Crohns Colitis. 2016;10:429–36.

    Article  Google Scholar 

  11. 11.

    Severs M, Spekhorst LM, Mangen MJ, Dijkstra G, Löwenberg M, Hoentjen F, et al. Sex-related differences in patients with inflammatory bowel disease: Results of 2 prospective cohort studies. Inflamm Bowel Dis. 2018;24:1298–306.

    Article  Google Scholar 

  12. 12.

    Vegh Z, Kurti Z, Gonczi L, Golovics PA, Lovasz BD, Szita I, et al. Association of extraintestinal manifestations and anaemia with disease outcomes in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51:848–54.

    CAS  Article  Google Scholar 

  13. 13.

    Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis. 2008;40(Suppl. 2):S253–9.

    Article  Google Scholar 

  14. 14.

    Singla MB, Eickhoff C, Betteridge J. Extraintestinal manifestations are common in obese patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23:1637–42.

    Article  Google Scholar 

  15. 15.

    Satsangi J, Grootscholten C, Holt H, Jewell DP. Clinical patterns of familial inflammatory bowel disease. Gut. 1996;38:738–41.

    CAS  Article  Google Scholar 

  16. 16.

    Herzog D, Fournier N, Buehr P, Rueger V, Koller R, Heyland K, et al. Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications. Eur J Gastroenterol Hepatol. 2018;30:598–607.

    Article  Google Scholar 

  17. 17.

    Hata K, Ishii H, Anzai H. Preoperative extraintestinal manifestations associated with chronic pouchitis in Japanese patients with ulcerative colitis after ileal pouch-anal anastomosis: a retrospective study. Inflamm Bowel Dis. 2017;23:1019–24.

    Article  Google Scholar 

  18. 18.

    Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44:1–13.

    CAS  Article  Google Scholar 

  19. 19.

    Monsén U, Sorstad J, Hellers G, Johansson C. Extracolonic diagnoses in ulcerative colitis: An epidemiological study. Am J Gastroenterol. 1990;85:711–6.

    PubMed  Google Scholar 

  20. 20.

    Levine A, Koletzko S, Turner D, Escher JC, Cucchiara S, de Ridder L, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pedia Gastroenterol Nutr. 2014;58:795–806.

    CAS  Google Scholar 

  21. 21.

    Levine A, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314–21.

    Article  Google Scholar 

  22. 22.

    Turner D, Griffiths AM, Walters TD, Seah T, Markowitz J, Pfefferkorn M, et al. Appraisal of the pediatric Crohn’s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010;105:2085–92.

    Article  Google Scholar 

  23. 23.

    Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology. 2007;133:423–32.

    Article  Google Scholar 

  24. 24.

    Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:63–68.

    Article  Google Scholar 

  25. 25.

    Guariso G, Gasparetto M, Visonà Dalla Pozza L, D’Incà R, Zancan L, Sturniolo G, et al. Inflammatory bowel disease developing in paediatric and adult age. J Pedia Gastroenterol Nutr. 2010;51:698–707.

    Article  Google Scholar 

  26. 26.

    Dotson JL, Hyams JS, Markowitz J, LeLeiko NS, Mack DR, Evans JS, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pedia Gastroenterol Nutr. 2010;51:140–5.

    Article  Google Scholar 

  27. 27.

    Stawarski A, Iwanczak B, Krzesiek E, Iwańczak F. Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease. Pol Merkur Lek. 2006;20:22–5.

    Google Scholar 

  28. 28.

    Corica D, Romano C. Renal involvement in inflammatory bowel diseases. J Crohns Colitis. 2016;10:226–35.

    Article  Google Scholar 

  29. 29.

    Yerushalmy-Feler A, Ben-Tov A, Weintraub Y, Amir A, Galai T, Moran-Lev H, et al. High and low body mass index may predict severe disease course in children with inflammatory bowel disease. Scand J Gastroenterol. 2018;53:708–13.

    Article  Google Scholar 

  30. 30.

    Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance. J Clin Investig. 1995;95:2409–15.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Shlomi Cohen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cohen, S., Padlipsky, J. & Yerushalmy-Feler, A. Risk factors associated with extraintestinal manifestations in children with inflammatory bowel disease. Eur J Clin Nutr 74, 691–697 (2020). https://doi.org/10.1038/s41430-019-0490-1

Download citation

Further reading

Search

Quick links